X Deng1, J Cheng2, M Shen2. 1. Department of Endocrinology, Wuhan Third Hospital, Wuhan University, 430062, Wuhan, China. dengxiangqun@hotmail.com. 2. Department of Endocrinology, Changzhou No. 2 People's Hospital, Nanjing Medical University, 213003, Changzhou, China.
Abstract
BACKGROUND: It is well established that the activation of the renin-angiotensin system (RAS) and the oxidative stress caused by hyperglycemia are major mediators of the development and progression of diabetic nephropathy (DN). Vitamin D may be important in maintaining podocyte health, preventing epithelial-to-mesenchymal transformation, and suppressing renin gene expression and inflammation, but its mechanism requires clarification. This study evaluated the specific mechanism of vitamin D to DN improvement. METHODS: We induced a rat model of diabetes with an intraperitoneal injection of streptozotocin (60 mg/kg). The streptozotocin-induced diabetic rats were fed normal chow for about 2 months to induce the DN model. The DN rats were then treated with irbesartan and/or calcitriol, administered intragastrically about 1 month. RESULTS: The rats displayed the early characteristics of DN, including increased microalbuminuria, obvious hypertrophic kidney, and a markedly increased kidney weight/bodyweight ratio. Vitamin D inhibited the compensatory increase in renin expression. Malondialdehyde, which reflects oxidative stress levels, was elevated in the DN group rats and their antioxidant capacity was significantly reduced. The irbesartan and calcitriol interventions markedly improved the renal pathology and pathophysiological changes. Irbesartan combined with vitamin D (calcitriol) more effectively ameliorated DN than irbesartan alone. CONCLUSIONS: Vitamin D combined with angiotensin II type 1 receptor blockers exerts a synergistic effect on the treatment of DN, not only by inhibiting renin but also by reducing oxidative stress and increasing the renal antioxidant capacity.
BACKGROUND: It is well established that the activation of the renin-angiotensin system (RAS) and the oxidative stress caused by hyperglycemia are major mediators of the development and progression of diabetic nephropathy (DN). Vitamin D may be important in maintaining podocyte health, preventing epithelial-to-mesenchymal transformation, and suppressing renin gene expression and inflammation, but its mechanism requires clarification. This study evaluated the specific mechanism of vitamin D to DN improvement. METHODS: We induced a rat model of diabetes with an intraperitoneal injection of streptozotocin (60 mg/kg). The streptozotocin-induced diabeticrats were fed normal chow for about 2 months to induce the DN model. The DN rats were then treated with irbesartan and/or calcitriol, administered intragastrically about 1 month. RESULTS: The rats displayed the early characteristics of DN, including increased microalbuminuria, obvious hypertrophic kidney, and a markedly increased kidney weight/bodyweight ratio. Vitamin D inhibited the compensatory increase in renin expression. Malondialdehyde, which reflects oxidative stress levels, was elevated in the DN group rats and their antioxidant capacity was significantly reduced. The irbesartan and calcitriol interventions markedly improved the renal pathology and pathophysiological changes. Irbesartan combined with vitamin D (calcitriol) more effectively ameliorated DN than irbesartan alone. CONCLUSIONS:Vitamin D combined with angiotensin II type 1 receptor blockers exerts a synergistic effect on the treatment of DN, not only by inhibiting renin but also by reducing oxidative stress and increasing the renal antioxidant capacity.
Entities:
Keywords:
Angiotensin II type 1 receptor blockers; Diabetic nephropathy; Oxidative stress; Rats; Vitamin D
Authors: Pedro Montilla; Montserrat Barcos; Maria C Munoz; Inmaculada Bujalance; Juan R Munoz-Castaneda; Isaac Tunez Journal: J Biochem Mol Biol Date: 2005-09-30
Authors: Weihua Yuan; Wei Pan; Juan Kong; Wei Zheng; Frances L Szeto; Kari E Wong; Ronald Cohen; Anna Klopot; Zhongyi Zhang; Yan Chun Li Journal: J Biol Chem Date: 2007-08-09 Impact factor: 5.157
Authors: María Jesús Izquierdo; Mónica Cavia; Pilar Muñiz; Angel L M de Francisco; Manuel Arias; Javier Santos; Pedro Abaigar Journal: BMC Nephrol Date: 2012-11-27 Impact factor: 2.388
Authors: João Soares Felício; Alana Ferreira de Oliveira; Amanda Soares Peixoto; Ana Carolina Contente Braga de Souza; João Felício Abrahão Neto; Franciane Trindade Cunha de Melo; Carolina Tavares Carvalho; Manuela Nascimento de Lemos; Sávio Diego Nascimento Cavalcante; Fabricio de Souza Resende; Márcia Costa Dos Santos; Ana Regina Motta; Luísa Corrêa Janaú; Elizabeth Sumi Yamada; Karem Miléo Felício Journal: Front Endocrinol (Lausanne) Date: 2017-08-14 Impact factor: 5.555
Authors: João Soares Felício; Hana Andrade de Rider Britto; Pedro Celeira Cortez; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Lorena Vilhena de Moraes; Vitória Teixeira de Aquino; Fernanda de Souza Parente; Natércia Neves Marques de Queiroz; João Felício Abrahão Neto; Angélica Leite de Alcântara; Wanderson Maia da Silva; Norberto Jorge Kzan de Souza Neto; Pedro Paulo Freire Piani; Ícaro José Araújo de Souza; Lilian de Souza D'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Nivin Mazen Said; Gabriela Nascimento de Lemos; Franciane Trindade Cunha de Melo; Daniela Lopes Gomes; Ana Carolina Contente Braga de Souza; Melissa de Sá Oliveira Dos Reis; Valéria Suênya Galvão Leal; Isabel Jane Campos Lobato; Karem Miléo Felício Journal: Front Endocrinol (Lausanne) Date: 2021-10-07 Impact factor: 5.555